In conclusion, we confirmed that the introduction of UDCA treatment decreased the expression of miR-34a, miR-506 and sCD163 in the serum of PBC patients, which may lead to the suppression of pro-inflammatory signaling and result in the reduction of serum TREM-2 levels. The gene discussed is CD163; the disease is primary biliary cholangitis.